GeneCentric
1 known investors
GeneCentric develops ExpressCT, a fragmentomics technology that extracts gene expression measurements from circulating tumor DNA sequencing data to enable expression-based biomarkers for cancer diagnostics and precision oncology. The company serves biopharma, diagnostics companies, and commercial laboratories.